Pages that link to "Q37002423"
Jump to navigation
Jump to search
The following pages link to Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay (Q37002423):
Displaying 50 items.
- Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis (Q21261905) (← links)
- Methotrexate for primary biliary cirrhosis (Q24235442) (← links)
- Non-invasive Markers of Liver Fibrosis: Adjuncts or Alternatives to Liver Biopsy? (Q26744631) (← links)
- Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists (Q26796355) (← links)
- Strategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014. (Q28082065) (← links)
- Prospective comparison of magnetic resonance imaging to transient elastography and serum markers for liver fibrosis detection. (Q30357769) (← links)
- Invasive and non-invasive diagnosis of cirrhosis and portal hypertension (Q30439743) (← links)
- Comparison of accuracy of fibrosis degree classifications by liver biopsy and non-invasive tests in chronic hepatitis C (Q30471886) (← links)
- Evolving therapies for liver fibrosis (Q30539166) (← links)
- Prospective validation of ELF test in comparison with Fibroscan and FibroTest to predict liver fibrosis in Asian subjects with chronic hepatitis B. (Q34359330) (← links)
- Role of simple biomarkers in predicting fibrosis progression in HCV infection (Q34385138) (← links)
- Biopsy-controlled liver fibrosis staging using the enhanced liver fibrosis (ELF) score compared to transient elastography (Q34532528) (← links)
- Serum GP73, a marker for evaluating progression in patients with chronic HBV infections (Q34589487) (← links)
- Performance of Enhanced Liver Fibrosis test and comparison with transient elastography in the identification of liver fibrosis in patients with chronic hepatitis B infection. (Q34981143) (← links)
- The performance of enhanced liver fibrosis (ELF) test for the staging of liver fibrosis: a meta-analysis (Q35149314) (← links)
- Primary biliary cirrhosis and Sjögren's syndrome: autoimmune epithelitis (Q36599248) (← links)
- Risk factors for hepatic decompensation in patients with primary biliary cirrhosis (Q36637728) (← links)
- Association of HIV, Hepatitis C Virus, and Liver Fibrosis Severity With the Enhanced Liver Fibrosis Score (Q36654566) (← links)
- Enhanced liver fibrosis marker as a noninvasive predictor of mortality in HIV/hepatitis C virus-coinfected women from a multicenter study of women with or at risk for HIV. (Q36715064) (← links)
- Isolated Hepatitis B Core Antibody Status Is Not Associated With Accelerated Liver Disease Progression in HIV/Hepatitis C Coinfection (Q37014002) (← links)
- Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. (Q37086216) (← links)
- Natural history and management of primary biliary cirrhosis (Q37355843) (← links)
- Prolonged fibroblast growth factor 19 response in patients with primary sclerosing cholangitis after an oral chenodeoxycholic acid challenge (Q37584099) (← links)
- Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies. (Q37587875) (← links)
- Evaluation of the aspartate aminotransferase/platelet ratio index and enhanced liver fibrosis tests to detect significant fibrosis due to chronic hepatitis C. (Q37627015) (← links)
- Evolving challenges in hepatic fibrosis (Q37768335) (← links)
- Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic (Q37825556) (← links)
- Biomarkers of liver fibrosis: what lies beneath the receiver operating characteristic curve? (Q37897194) (← links)
- Anti-fibrotic therapy: lost in translation? (Q37980899) (← links)
- Mechanisms and biomarkers of apoptosis in liver disease and fibrosis (Q38008400) (← links)
- Molecular serum markers of liver fibrosis. (Q38032835) (← links)
- Translating an understanding of the pathogenesis of hepatic fibrosis to novel therapies (Q38073028) (← links)
- Review article: The prevention and reversal of hepatic fibrosis in autoimmune hepatitis (Q38175465) (← links)
- Non-invasive monitoring of liver fibrosis. (Q38262486) (← links)
- Emerging drugs for the treatment of Primary Biliary Cholangitis (Q38744215) (← links)
- Hyaluronic acid algorithm-based models for assessment of liver fibrosis: translation from basic science to clinical application (Q38791466) (← links)
- Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-centre study (Q38924675) (← links)
- Enhanced liver fibrosis test in patients with psoriasis, psoriatic arthritis and rheumatoid arthritis: a cross-sectional comparison with procollagen-3 N-terminal peptide (P3NP). (Q39124718) (← links)
- Geoepidemiology and changing mortality in primary biliary cholangitis (Q39213467) (← links)
- Enhanced liver fibrosis test using ELISA assay accurately discriminates advanced stage of liver fibrosis as determined by transient elastography fibroscan in treatment naïve chronic HCV patients. (Q39324556) (← links)
- Noninvasive methods for the assessment of liver fibrosis: A window open on the future? (Q39702780) (← links)
- Noninvasive serum models to predict significant liver related events in chronic hepatitis C. (Q40151847) (← links)
- Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: A proof-of-concept study (Q40898741) (← links)
- Serum Wisteria floribunda Agglutinin-Positive Mac-2-Binding Protein Level Predicts Liver Fibrosis and Prognosis in Primary Biliary Cirrhosis (Q41009473) (← links)
- ELF score ≥9.8 indicates advanced hepatic fibrosis and is influenced by age, steatosis and histological activity (Q42177206) (← links)
- Combination of blood tests for significant fibrosis and cirrhosis improves the assessment of liver-prognosis in chronic hepatitis C. (Q42215056) (← links)
- Evolution of noninvasive tests of liver fibrosis is associated with prognosis in patients with chronic hepatitis C. (Q42237621) (← links)
- Liver stiffness 1 year after transplantation predicts clinical outcomes in patients with recurrent hepatitis C. (Q42244049) (← links)
- Diagnostic accuracy of enhanced liver fibrosis test to assess liver fibrosis in patients with chronic hepatitis C. (Q42264092) (← links)
- Non-invasive assessment of liver fibrosis (Q42406716) (← links)